Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery

Molecular Devices and HeartBeat.bio AG have entered into a co-development agreement to commercialize a first-of-its-kind automated offering that will enable researchers to reliably scale production of Cardioids and advance cardiac drug discovery.

BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research

BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

DNAnexus Selected as Platform Provider of the Trusted Research Environment for UK’s Largest Health Research Program

DNAnexus awarded a 3-year contract by Our Future Health to provide a scalable, cloud-based trusted research environment for the large-scale population research program that aims to recruit up to 5 million volunteers. Approved researchers from the global life sciences, healthcare, and academic communities will be able to use the DNAnexus platform to securely explore and analyze the de-identified data.

BOC Sciences August Promotion: Comprehensive Labeled Peptides with Stable Quality

As a pioneer in stable isotopic labeling chemistry, BOC Sciences develops a large variety of SIL compounds. Its promotion of labeled peptides, the increasingly used materials for convenient detection in research, is on the boil in August.

BOC Sciences 2022 Free Webinar: Viral RNA Modifications and Implications for Novel Therapeutics

BOC Sciences grandly announced the schedule of a free webinar on September 19th, 2022, at 11:00 EDT, which is a laudable event centering on the hot spot of RNA research during the pandemic.

BOC Sciences August Promotion: Compound Docking Solutions for Drug Discovery

As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets.

BioIVT Highlights ADME-Tox Research Advances at ISSX/MDO 2022

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.

Verana Health to Highlight the Value of Curated Real-World Data at the American College of Epidemiology 2022 Annual Meeting

Research projects demonstrate the value of using quality, de-identified real-world data (RWD) curated from electronic health records (EHRs) to derive actionable insights about missing data. Researchers used de-identified RWD from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and the American Academy of Neurology Axon Registry®.

VERICHEM NOW OFFERS MULTI-LEVEL, LIQUID STABLE CLINICAL REFERENCE MATERIALS FOR ETHANOL TESTING

Trinity Health Partners with Orexo US to Expand Patient Access to Digital Therapeutics

AccessDx Laboratory’s Dr. Houda Hachad Named to PharmaVoice 100

mdgroup Chief Operating Officer LaQuinta Jernigan Honoured as one of 100 Most Inspiring People in Life Sciences 2022

mdgroup Chief Operating Officer LaQuinta Jernigan Honoured as one of 100 Most Inspiring People in Life Sciences 2022 Recognized for championing diversity and collaboration within the clinical trials industry

Hydrophilic Polymers Exhibit Boundless Opportunities for Multiple Fields

Insights, Strategies, and Practical Suggestions on Pre-formulation Studies for Pharmaceuticals

Creative Peptides Released One-Stop Solution for All Peptide Drug Conjugate Needs

Creative Biogene Introduces One-Stop Microbial Genome Editing Services

BOC Sciences Developed Strain Expression Systems to Enhance Fermentation Productivity

PseudoUridine Phosphoramidites for Efficient and Reliable Syntheses of RNA Oligonucleotides

learwater and CynergisTek Complete Merger, Bringing Together Cybersecurity, Privacy, and Compliance Leaders

Clearwater announced today that its planned merger with CynergisTek has been completed, bringing together two market leaders who are joining forces to serve the cybersecurity, privacy, and compliance needs of healthcare organizations, as well as those in other highly regulated industries. As a result of the transaction, CynergisTek is now a privately owned company and will operate as a subsidiary of Clearwater, aside Clearwater’s recently acquired TECH LOCK Division. Common mission, values, and customer focus among all three companies provide a strong foundation to create a clear market leader in healthcare cybersecurity and compliance.